Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOB | P27338 | 2/20 | 0.46 |
| ▸ | MAOA | P21397 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 2/20 | 0.46 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.41 |
| ▸ | PCSK9 | Q8NBP7 | 1/20 | 0.41 |
| ▸ | LIPG | Q9Y5X9 | 2/20 | 0.41 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.40 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.40 |
| ▸ | P2RX3 | P56373 | 1/20 | 0.39 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.39 |
| ▸ | BTK | Q06187 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12199848 | 0.92 | GPR119 (0.50) | MAOBMAOAGPR119CHEK2DYRK1A | |
| SCHEMBL649121 | 0.87 | CHRNA7 (0.44) | HDAC4GPR119HDAC6 | |
| SCHEMBL4350210 | 0.86 | MAOB (0.48) | MAOBMAOAHDAC4HDAC6PCSK9 | |
| SCHEMBL647504 | 0.85 | UTS2R (0.46) | HDAC4GPR119HDAC6DYRK1A | |
| SCHEMBL2504574 | 0.84 | HDAC4 (0.46) | HDAC4GPR119CHEK2HDAC6PRKAA2 | |
| SCHEMBL61833 | 0.84 | HDAC4 (0.49) | HDAC4GPR119CHEK2HDAC6PRKAA2 | |
| SCHEMBL2510687 | 0.84 | DRD4 (0.47) | MAOBMAOAPCSK9PRKAA2 | |
| SCHEMBL648509 | 0.83 | NPC1 (0.43) | HDAC4GPR119DYRK1ABTK | |
| SCHEMBL62615 | 0.82 | HDAC4 (0.51) | HDAC4GPR119HDAC6PRKAA2 | |
| SCHEMBL650732 | 0.82 | EPHX2 (0.48) | HDAC4GPR119PRKAA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 26 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8314107-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | claimed |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | claimed |
| CN-112079769-A | Carboxamide compounds for the treatment of metabolic disorders | 里格尔药品股份有限公司 | 2020-12-15 | — | — | CN | disclosed |
| CN-106928211-B | Carboxamide compounds for the treatment of metabolic disorders | 里格尔药品股份有限公司 | 2020-09-08 | — | — | CN | disclosed |
| US-9511058-B2 | Methods for using carboxamide, sulfonamide and amine compounds | RIGEL PHARMACEUTICALS INC. (US) | 2016-12-06 | — | — | US | disclosed |
| US-9409884-B2 | 5- or 6-substituted benzofuran-2-carboxamide compounds and methods for using them | RIGEL PHARMACEUTICALS, INC. (US) | 2016-08-09 | — | — | US | disclosed |
| US-9353111-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2016-05-31 | — | — | US | disclosed |
| US-20160122321-A1 | Carboxamide Compounds and Methods for Using the Same | MIDCAP FINANCIAL TRUST | 2016-05-05 | — | — | US | disclosed |
| US-9255085-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2016-02-09 | — | — | US | disclosed |
| US-20150232451-A1 | Carboxamide Compounds and Methods for Using the Same | MIDCAP FINANCIAL TRUST | 2015-08-20 | — | — | US | disclosed |
| US-9062052-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2015-06-23 | — | — | US | disclosed |
| US-20140148467-A1 | Carboxamide Compounds and Methods for Using the Same | RIGEL PHARMACEUTICALS, INC. (US) | 2014-05-29 | — | — | US | disclosed |
| US-20130023660-A1 | Carboxamide Compounds and Methods for Using the Same | RIGEL PHARMACEUTICALS, INC. (US) | 2013-01-24 | — | — | US | disclosed |
| US-8314107-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-8314107-B2 | Carboxamide compounds and methods for using the same | RIGEL PHARMACEUTICALS, INC. (US) | 2012-11-20 | — | — | US | disclosed |
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | RIGEL PHARMACEUTICALS, INC. (US) | 2011-10-06 | — | — | US | disclosed |
| EP-2276761-A1 | CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | Rigel Pharmaceuticals, Inc. (US) | 2011-01-26 | — | — | EP | disclosed |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | RIGEL PHARMACEUTICALS, INC. (US) | 2009-11-05 | — | — | US | disclosed |
| WO-2009132136-A1 | CARBOXAMIDE COMPOUNDS FOR THE TREATMENT OF METABOLIC DISORDERS | RIGEL PHARMACEUTICALS, INC. (US) | 2009-10-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110245222-A1 | Methods for Using Carboxamide, Sulfonamide and Amine Compounds | CS, SHMT2, GOT2 | MAOB 441/4885MAOA 444/4885HDAC4 335/4885 |
| US-20140148467-A1 | Carboxamide Compounds and Methods for Using the Same | PC, AK2, PRKAA2 | MAOB 2083/4885MAOA 2092/4885HDAC4 838/4885 |
| US-20160122321-A1 | Carboxamide Compounds and Methods for Using the Same | PC, AK2, PRKAA2 | MAOB 2083/4885MAOA 2092/4885HDAC4 838/4885 |
| US-20130023660-A1 | Carboxamide Compounds and Methods for Using the Same | PC, AK2, PRKAA2 | MAOB 2083/4885MAOA 2092/4885HDAC4 838/4885 |
| US-20150232451-A1 | Carboxamide Compounds and Methods for Using the Same | PC, AK2, PRKAA2 | MAOB 2083/4885MAOA 2092/4885HDAC4 838/4885 |
| US-20090275609-A1 | Carboxamide Compounds and Methods for Using The Same | PC, AK2, PRKAA2 | MAOB 2083/4885MAOA 2092/4885HDAC4 838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.